Boardroom Alpha
Boardroom Alpha
PLYX · Additional Proxy Materials (DEFA14A) · Filed July 28, 2026

Polaryx Therapeutics Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
July 28, 2026
Ticker
PLYX
Accession
0001213900-26-082345
Boardroom Alpha · Filing insights

Polaryx Therapeutics' board nominates two Class I directors (Alex Yang and Mitchel Berger) and urges votes FOR both nominees and FOR Grant Thornton LLP as auditor.

About Polaryx Therapeutics Inc
Market cap
$99M
Board grade
D
Sector
Healthcare
Last annual meeting: Sep 10, 2026 · View full Polaryx Therapeutics Inc profile →

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

SCHEDULE 14A INFORMATION

 

 

 

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.    )

 

Filed by the Registrant  
Filed by a party other than the Registrant  

 

Check the appropriate box:

 

  Preliminary Proxy Statement
  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
  Definitive Proxy Statement
  Definitive Additional Materials
  Soliciting Material under § 240.14a-12

 

Polaryx Therapeutics, Inc.

(Name of Registrant as Specified In Its Charter)

 

 

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):

 

  No fee required
  Fee paid previously with preliminary materials
  Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11

 

 

 

 

 

1. Election of Class I Directors: NOMINEES : Alex Yang, J.D., LL.M Mitchel Berger, M.D. Important Notice of Availability of Proxy Materials for the Annual Meeting of Shareholders of Polaryx Therapeutics, Inc. to be held on September 10, 2026, at 9:00 a.m. Eastern Time Virtual meeting: edge.media - server.com/mmc/p/3xysc6n4 (password: polaryx2026) This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. If you want to receive a paper or e - mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. To facilitate timely delivery, please make the request as instructed below before August 27, 2026. Please visit www.eqproxyportal.com/29861/annual , where the following materials are available for view: • Notice of Annual Meeting of Shareholders • Proxy Statement • Proxy Card • Annual Report on Form 10 - K TO REQUEST MATERIAL: TELEPHONE : 1 - 888 - Proxy - NA ( 1 - 888 - 776 - 9962 ) or + 1 - 201 - 299 - 6210 worldwide E - MAIL : helpAST@equiniti . com WEBSITE : us . astfinancial . com/OnlineProxyVoting/ProxyVoting/RequestMaterials ONLINE : To access your online proxy card, please visit www . voteproxy . com and follow the on - screen instructions or scan the QR code with your smartphone . You may enter your voting instructions at www . voteproxy . com until 11 : 59 p . m . Eastern Time the day before the meeting . MAIL : You may request a proxy card by following the instructions above . TO VOTE: COMPANY NUMBER ACCOUNT NUMBER CONTROL NUMBER Please note that you cannot use this notice to vote by mail. 2 . Proposal to ratify the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for fiscal year ending December 31 , 2026 . THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR ALL NOMINEES” IN THE ELECTION OF CLASS I DIRECTORS, AND “FOR” PROPOSAL 2 .

 

 

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Polaryx Therapeutics Inc (PLYX)

Reference

Frequently asked questions

When did Polaryx Therapeutics Inc file this DEFA14A?
Polaryx Therapeutics Inc (PLYX) filed this Additional Proxy Materials (DEFA14A) with the SEC on July 28, 2026. The accession number assigned by EDGAR is 0001213900-26-082345.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Polaryx Therapeutics' board nominates two Class I directors (Alex Yang and Mitchel Berger) and urges votes FOR both nominees and FOR Grant Thornton LLP as auditor. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Polaryx Therapeutics Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Polaryx Therapeutics Inc has filed under CIK 2075320, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer